S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

Bolt Biotherapeutics (BOLT) Insider Trading & Ownership

$1.11
-0.04 (-3.48%)
(As of 04/17/2024 ET)

Bolt Biotherapeutics (NASDAQ:BOLT) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
28.40%
Number Of
Insiders Buying
(Last 12 Months)
1
Amount Of
Insider Buying
(Last 12 Months)
$11,233.22
Number Of
Insiders Selling
(Last 12 Months)
3
Amount Of
Insider Selling
(Last 12 Months)
$125,191.15
Get BOLT Insider Trade Alerts

Want to know when executives and insiders are buying or selling Bolt Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

BOLT Insider Buying and Selling by Quarter

Bolt Biotherapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/12/2023William P QuinnCFOBuy7,500$0.95$7,125.00  
12/6/2023William P QuinnCFOBuy2,500$0.78$1,950.00  
11/29/2023Edgar EnglemanDirectorSell25,805$0.91$23,482.55  
11/20/2023Edgar EnglemanDirectorSell31,257$0.92$28,756.44  
11/20/2023Vivo Capital Viii, LlcMajor ShareholderSell54,700$0.92$50,324.00  
11/16/2023Edgar EnglemanDirectorSell8,571$0.96$8,228.16  
11/16/2023Vivo Capital Viii, LlcMajor ShareholderSell15,000$0.96$14,400.00  
6/6/2023William P QuinnCFOBuy1,829$1.18$2,158.22  
(Data available from 1/1/2013 forward)

BOLT Insider Trading Activity - Frequently Asked Questions

Who is on Bolt Biotherapeutics's Insider Roster?

The list of insiders at Bolt Biotherapeutics includes Edgar Engleman, Holdings A/S Novo, Vivo Capital Viii, Llc, and William P Quinn. Learn more on insiders at BOLT.

What percentage of Bolt Biotherapeutics stock is owned by insiders?

28.40% of Bolt Biotherapeutics stock is owned by insiders. Learn more on BOLT's insider holdings.

Which Bolt Biotherapeutics insiders have been buying company stock?

The following insider purchased BOLT shares in the last 24 months: William P Quinn ($11,233.22).

How much insider buying is happening at Bolt Biotherapeutics?

Insiders have purchased a total of 11,829 BOLT shares in the last 24 months for a total of $11,233.22 bought.

Which Bolt Biotherapeutics insiders have been selling company stock?

The following insiders have sold BOLT shares in the last 24 months: Edgar Engleman ($60,467.15), Holdings A/S Novo ($1,600,000.00), and Vivo Capital Viii, Llc ($64,724.00).

How much insider selling is happening at Bolt Biotherapeutics?

Insiders have sold a total of 935,333 Bolt Biotherapeutics shares in the last 24 months for a total of $1,725,191.15 sold.


More Insider Trading Tools from MarketBeat

This page (NASDAQ:BOLT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners